PedAM
Pediatric Disease Annotations & Medicines
| Disease | portal hypertension |
| Symptom | C0023890|cirrhosis |
| Sentences | 141 |
| PubMedID- 21606920 | The experimental study of liver cirrhosis with portal hypertension syndrome, modeled in 38 dogs, has been performed. |
| PubMedID- 24350068 | Liver cirrhosis causes 90% of portal hypertension in the western world, which leads to the development of porto-systemic collaterals, this in turn triggers the formation of the lower esophageal and gastric cardiac varices. |
| PubMedID- 20500867 | • childs b or c cirrhosis or with evidence of severe portal hypertension by history, endoscopy, or radiologic studies or with evidence of moderate to severe ascites. |
| PubMedID- 24574834 | Variceal bleeding is one of the most fatal complications of portal hypertension in patients with liver cirrhosis . |
| PubMedID- 26205377 | The incidence of portal hypertension (pht) with post-hepatitis cirrhosis is higher in china than elsewhere worldwide. |
| PubMedID- 24729881 | 17 (7%) patients had a mild hepatic comorbidity (score 1) (bilirubin > uln to 1.5 × uln or ast/alt > uln to 2.5 × uln) and 1 patient additional liver cirrhosis with portal hypertension (score 3). |
| PubMedID- 21831314 | Sixty-seven patients were not enrolled in the study for the following reasons: (1)cirrhosis and evidence of portal hypertension (n = 17); (2) declined staging procedures and preferred to wait for new hcv therapies (n = 15); (3) omission of survey completion during early months on study implementation (n = 13); (4) declined any medical treatment or evaluation (n = 9); (5) hcv antibody positive and hcv rna negative and did not need hcv therapy (n = 7); and (6) transferring care to a different city and clinical staging could not be completed (n = 6). |
| PubMedID- 26412302 | Additionally, neo-angiogenesis has been identified as a key mechanism in the progression of liver cirrhosis with portal hypertension3. |
| PubMedID- 25454305 | Portal vein thrombosis (pvt) is a rare event in the general medical setting that commonly complicates cirrhosis with portal hypertension, and can also occur with liver tumors. |
| PubMedID- 26378453 | We investigated the relationship between copeptin and hemodynamic characteristics in an animal model bearing strong resemblance to human cirrhosis, including typical features of portal hypertension and the hyperdynamic circulation, but with a normal kidney function as shown previously and without the use of therapeutic interventions which may affect copeptin levels. |
| PubMedID- 24889902 | Phg, by definition, requires the presence of portal hypertension, with or without cirrhosis, whereas gave requires neither cirrhosis nor portal hypertension. |
| PubMedID- 25892988 | This study aimed to further investigate portal venous remodeling in the pathogenesis of liver cirrhosis with portal hypertension, thereby guiding its prevention and treatment. |
| PubMedID- 25658710 | However, advanced liver disease, defined as multilobular cirrhosis frequently with portal hypertension, occurs in only 5–10% of individuals with cf . |
| PubMedID- 25256370 | Background: decreased antithrombin iii (atiii) activity and large splenic vein diameter (svd) are risk factors for portal vein thrombosis (pvt) after splenectomy in liver cirrhosis with portal hypertension. |
| PubMedID- 23520531 | Ls is currently the best non-invasive surrogate predictor of portal hypertension in patients with cirrhosis , and its prognostic value was recently confirmed by cross-sectional studies about the presence of gastroesophageal varices , and longitudinal studies with hard clinical end-points such as the appearance of clinical decompensation and hepatocellular carcinoma . |
| PubMedID- 26530427 | Moderate and severe liver diseases were cirrhosis combined with portal hypertension without and with history of varices bleeding . |
| PubMedID- 21223822 | Methods: the rats of hepatic cirrhosis with portal hypertension were randomly assigned into 1 control group, 1 model group and 4 treatment groups (ns, hgf, ins, hgf + ins). |
| PubMedID- 26385087 | Thus, jak2 inhibitors, already in clinical use for other indications, might be a new approach to treat cirrhosis with portal hypertension. |
| PubMedID- 20339175 | Levels of globulins significantly increased in cirrhosis with portal hypertension (p<0.001). |
| PubMedID- 25657603 | Progressive cirrhosis, with portal hypertension, is characterized by the development of portosystemic shunts and inadequately cleared circulating vasoactive substances eg, nitric oxide, vasoactive intestinal peptide, endocannabinoids, and bile salts, which create a state of splanchnic and arterial vasodilation, leading to ineffective central blood volume, initially compensated by high cardiac output.3,8 with worsening cirrhosis, systemic vascular resistance continues to fall, but cardiac compensation reaches a maximum. |
| PubMedID- 22086533 | However, she developed hepatic cirrhosis with portal hypertension. |
| PubMedID- 21371340 | Ce has made it possible to examine the small bowel mucosa directly and has allowed endoscopists to visualize the mucosal changes in cirrhosis patients with portal hypertension. |
| PubMedID- 20300546 | To prevent immediate and late sequelae of hepatolithiasis, such as suppurative cholangitis, septicemia, secondary biliary cirrhosis with resultant portal hypertension, bleeding varices, and hepatic failure 5, aggressive treatment is needed. |
| PubMedID- 23762144 | Eligible patients had hbv-induced cirrhosis with portal hypertension and gastroesophageal varices, as defined by endoscopy. |
| PubMedID- 23593273 | Indeed, a small clinical study evaluating the therapeutic potential of int-747 in regulating portal hypertension in patients with alcoholic cirrhosis has just completed (http://www.ukctg.nihr.ac.uk/trialdetails/isrctn22662520). |
| PubMedID- 25793622 | The development of portal hypertension in cirrhosis leads to a progressive decrease in the perfusion of the sinusoids, so that theoretically there is a reduction of sinusoidal perfusion. |
| PubMedID- 21485513 | Conclusion: the results indicated the effectiveness of therapy with flavonoids hesperidin with diasmin at portal hypertension in patients with alcoholic cirrhosis, which allows to include them in the complex treatment of medicamental prophylaxis of variceal bleeding. |
| PubMedID- 25655526 | cirrhosis in pregnancy with concomitant portal hypertension or esophageal varices is rare. |
| PubMedID- 23323255 | portal hypertension in cirrhosis leads to the development of collateral veins and portosystemic shunts, which in turn increase cardiac output and splanchnic blood flow, resulting in high portal venous inflow and persistent portal hypertension. |
| PubMedID- 22248963 | Caput medusae and palmar erythema are cardinal signs in cirrhosis of liver with portal hypertension. |
| PubMedID- 24829653 | However the normal platelet count and serum albumin in the patient is not in favor of advanced cirrhosis as the cause of portal hypertension. |
| PubMedID- 25606379 | Additionally, the authors reported that determination of low pon1 activity may serve as a useful additional test in assessing liver diseases including acute viral hepatitis b, chronic alcoholic hepatitis, cirrhosis with portal hypertension, hcv-related cirrhosis, hereditary hemochromatosis, and non-alcoholic fatty liver disease (nafld) (keskin et al., 2009; matineli et al., 2013; mogarekar and talekar, 2013). |
| PubMedID- 24436365 | Main outcome measurements: (1) incidence of cholestasis, (2) identification of risk factors for cholestasis, (3) association between the presence of cholestasis and mi and the development of clinically significant cf-associated liver disease (cfld) defined as multilobular cirrhosis with portal hypertension. |
| PubMedID- 25469784 | Purpose: to prospectively compare the technical success rate and accuracy of shear-wave elastography (swe) and transient elastography (te) for the detection of clinically significant portal hypertension (ph) in patients with advanced cirrhosis who are undergoing hepatic vein pressure gradient (hvpg) measurements. |
| PubMedID- 25834800 | If liver fibrosis progress to cirrhosis, complications arising from portal hypertension and functional hepatocyte loss develop. |
| PubMedID- 24974920 | Evaluation of cardiac systolic and diastolic functions in liver cirrhosis patients with portal hypertension conventional was done by conventional doppler echocardiography and tdi. |
| PubMedID- 25812120 | In some patients liver fibrosis leads to liver cirrhosis with portal hypertension, hepatocellular dysfunction and increased risk of hepatocellular carcinoma . |
| PubMedID- 22697282 | The performed magnetic resonance imaging examination confirmed the diagnosis of cirrhosis associated with portal hypertension and detected a vascular left transdiaphragmatic hernia. |
| PubMedID- 22114590 | We have a long-lasting interest in applying endoscopic ultrasound for the study of features of portal hypertension in patients with liver cirrhosis . |
| PubMedID- 25417057 | Liver stiffness measurement (lsm) is frequently used as non-invasive alternative for liver fibrosis including cirrhosis, which can lead to portal hypertension. |
| PubMedID- 19918014 | We defined liver disease as one of the following: 1) abnormal liver function tests, 2) cirrhosis with portal hypertension, or 3) use of supplementary bile acids. |
| PubMedID- 25561775 | Patient has a hcv cirrhosis with portal hypertension and esophageal varices f1. |
| PubMedID- 25539572 | Most portal hypertension results from cirrhosis but extra hepatic portal vein obstruction is the single commonest cause. |
| PubMedID- 23878740 | In western countries, ehpvo is second only to cirrhosis as a cause of portal hypertension, but its relative incidence is much lower compared with that in the developing countries. |
| PubMedID- 23606973 | Variceal hemorrhage is perhaps the most devastating portal hypertension-related complication in patients with cirrhosis, occurring in up to 30% of such individuals during the course of their illness. |
| PubMedID- 26464566 | Rectal varices are not an uncommon manifestation in cirrhosis with portal hypertension 1. |
| PubMedID- 22333168 | Conclusion: the arb is effective in reducing portal hypertension in patients with cirrhosis, which is similar to propranolol. |
| PubMedID- 24673975 | Thrombocytopenia: in time, liver cirrhosis leads to portal hypertension. |
| PubMedID- 23329943 | The diagnosis of cirrhosis with portal hypertension was based on a combination of clinical data such as jaundice, ascites, muscle wasting, cutaneous spider angiomas, ecchymosis, palmar erythema and flapping tremors; laboratory data such as decreased serum albumin and prolonged prothrombin time; and us findings such as coarsened echo texture and irregular liver surface. |
| PubMedID- 25912838 | However, it is not clear to what extent the progression of hepatitis c is modified once patients develop cirrhosis with severe portal hypertension (csph) (hvpg >/= 10 mm hg). |